Senescence

Jim Mellon donates £1 million to Oriel for aging research

Oxford University's Longevity science given a £1 million boost by donation. Oriel College, Oxford, is a focal point for the efforts to improve future health...

Telomeres – it’s not the end of the line

Sigh of relief as new study identifies possible drug treatments for telomere diseases – are we finally edging closing to unlocking the potential of...

Classifying aging as a disease – it’s all about the ‘how’

The hurdle of classifying aging as a disease, rather than an inevitability, has started to be overcome. Now Alex Zhavoronkov is pushing for us...

Longevity and the art of motorcycle maintenance

OpenCures' Kevin Perrott talks about empowering the consumer with their own health data. One of the Longevity sector’s leading voices came to the field relatively...

Longevity2020: Day 5 Recap

On Friday, the Longevity2020 online conference drew to a close, and the final day explored what people can be doing today to address their...

Longevity2020: Day 2 recap

Yesterday at Longevity2020 was all about rejuvenation therapies, bringing together some of the world’s leading luminaries in the fight against aging. Things kicked off with...

Oisín on aging as a disease and raising $5m seed

Co-founder Gary Hudson talks cell senescence, trials, spin-outs and the dilemma of treating age as a disease. Every entrepreneur in Longevity has a different story...

The quest to define biological age

Prof Steve Horvath, the founder of epigenetic age measurement, talks methylation clocks and the need for standardisation. A key speaker on the subject will be...

Building faster and better age-related clinical trials

Prof Ilaria Bellantuono seeks to build faster, better clinical trials for age-related disease with a focus on frailty. Multimorbidity – an individual suffering two or...

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

From machines to animals to humans

Exclusive with Prof Joao Pedro de Magalhaes: talking AI, indication expansion and animal models. “Will you still need me, will you still feed me, when...

Some good news: announcing Longevity2020

In these challenging times, with everyone working from home and conferences pushed-back to later this year, we had an idea: Longevity2020 While the world overcomes...

The Reason behind Longevity: start-up opportunities

We connected with Reason (the person) to get the inside track on hot areas for Longevity R&D.   Longevity.Technology: Advocacy runs through Reason like a...

Anti-aging drugs in MIT’s 10 Breakthrough Technologies 2020

For the last 20 years MIT Technology Review's Breakthrough Technologies 2020 has been assessing the way we live, work and invest.  Back in 2001, MIT...

Pathway to Longevity: get rid of zombie cells

Understanding the trigger for cellular senescence could help to forge new treatments for Longevity, stopping aging before it's started. Cellular senescence is a double-edged sword;...

Biosens raising £5m to support commercialisation

Start-up targets cell senescence therapies and near-term opportunities in advanced cosmetics market. The market for the development of anti-senescence therapeutics is on fire and we’ve...

Five Alarm Bio targets Alzheimer’s and skin aging

Stealthy anti-aging start-up kicks-off £2.6m fundraise to target both Alzheimer's and advanced cosmetics. Many of the companies working in the Longevity sector are playing their...

Next generation of senescence research

Teenage founder of Canadian start-up Biotein hunts a universal phenotype for senescent cells. Nina Khera (pictured above, first left) became interested in the challenge of...

Latest articles

Biomarkers for aging – a consensus is needed now more than ever

Slowing, stopping and even reversing aging – how can we research progress if we can't measure success? Biomarkers of aging are pretty important in the...

Hereafter: conversations in the afterlife

We speak to Dadbot creator James Vlahos about using conversational AI to better remember loved ones who have passed away; a very interesting step...

VR and AI used to generate structures to attack Coronavirus

Virtual reality and artificial intelligence come together to generate new chemicals from scratch which could be used against SARS-CoV-2. A new paper has outlined...

Exclusive video interview: Human Longevity Inc.’s Chairman

After $0.5bn cumulative investment, Human Longevity Inc. pivots into high-end medical services to seek scale and ROI. For a few years we tracked Human Longevity Inc.'s...